跳至主要内容
临床试验/NCT03159845
NCT03159845已完成2 期

A Mono-centric, No-profit, Case-control Study With Daily Oral Supplementation of Zinc Sulphate After Autologous Stem Cell Transplantation in Patients Affected by Multiple Myeloma

Azienda Ospedaliero, Universitaria Pisana1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2014年1月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
20
试验地点
1
主要终点
Thymic output improvement by flow cytometry

研究概览

简要总结

Patients affected by multiple myeloma undergone autologous stem cell transplantation (SCT) are enrolled at the moment of stem cell collection. They are randomized 1:1 in two groups at the moment of the graft. Patients of the Control group take only standard antimicrobial prophylaxis after SCT; the Sample group takes in addition a daily oral supplementation of Zinc Sulfate (600 mg/die) from day +5 until day +100 after SCT. Laboratory tests are performed on peripheral blood samples.

详细描述

Patients affected by multiple myeloma undergone autologous stem cell transplantation (SCT) are enrolled at the moment of stem cell collection. They are randomized 1:1 in two groups at the moment of the graft. Patients of the Control group take only standard antimicrobial prophylaxis after SCT; the Sample group takes in addition a daily oral supplementation of Zinc Sulfate (600 mg/die) from day +5 until day +100 after SCT. The aim of the study is to investigate the immune reconstitution in presence of Zinc, focused on thymic reconstitution. Laboratory tests are performed on peripheral blood samples, collected at 4 time-points: two before transplant (at the moment of the enrollment and the day before conditioning) and two after transplant (day +30 and +100).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • eligibility to stem cell transplantation

排除标准

  • allergy to Zinc
  • copper deficiency or Wilson's syndrome
  • patients who admit zinc assumption in other drugs

研究组 & 干预措施

Control

Active Comparator

patients undergone autologous stem cell transplantation. They take levofloxacin 500 mg/d, aciclovir 400 mg bid, fluconazole 200 mg bid from day +10 until day +30 after stem cell transplantation

干预措施: Levofloxacin 500Mg Oral Tablet (Drug)

Control

Active Comparator

patients undergone autologous stem cell transplantation. They take levofloxacin 500 mg/d, aciclovir 400 mg bid, fluconazole 200 mg bid from day +10 until day +30 after stem cell transplantation

干预措施: Fluconazole 200mg tab (Drug)

Control

Active Comparator

patients undergone autologous stem cell transplantation. They take levofloxacin 500 mg/d, aciclovir 400 mg bid, fluconazole 200 mg bid from day +10 until day +30 after stem cell transplantation

干预措施: Acyclovir 400 MG (Drug)

Zinc

Experimental

patients undergone autologous stem cell transplantation. They take the same antimicrobial prophylaxis of patients of the Control group, and, in addition, a daily oral supplementation of Zinc Sulfate, 600 mg/die, uncoated tabs, from day +5 until day +100 after transplant

干预措施: Zinc Sulfate Oral Product (Drug)

Zinc

Experimental

patients undergone autologous stem cell transplantation. They take the same antimicrobial prophylaxis of patients of the Control group, and, in addition, a daily oral supplementation of Zinc Sulfate, 600 mg/die, uncoated tabs, from day +5 until day +100 after transplant

干预措施: Levofloxacin 500Mg Oral Tablet (Drug)

Zinc

Experimental

patients undergone autologous stem cell transplantation. They take the same antimicrobial prophylaxis of patients of the Control group, and, in addition, a daily oral supplementation of Zinc Sulfate, 600 mg/die, uncoated tabs, from day +5 until day +100 after transplant

干预措施: Fluconazole 200mg tab (Drug)

Zinc

Experimental

patients undergone autologous stem cell transplantation. They take the same antimicrobial prophylaxis of patients of the Control group, and, in addition, a daily oral supplementation of Zinc Sulfate, 600 mg/die, uncoated tabs, from day +5 until day +100 after transplant

干预措施: Acyclovir 400 MG (Drug)

结局指标

主要结局

Thymic output improvement by flow cytometry

时间窗: days +30, +100 after transplant

Measure of circulating T naive lymphocytes by 8-colour flow-cytometry. T naive are identified as CD4+/CD8+ lymphocytes with the coexpression of CD45RA, CD27, CD28. The value is estimated as number of T naive/mcL

Thymic output improvement by TRECs

时间窗: increase of TRECs levels from day +30 until day +100 after transplant

Measure of T cell receptor excision circles levels on peripheral lymphocytes (TRECs), calculated as number of copies of TRECs/mcLin droplet digital PCR

次要结局

  • Variations in circulating lymphocyte populations(days +30, +100 after transplant)
  • Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability](days +30, +100 after transplant)
  • Immune competence(days +30, +100 after transplant)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Lorenzo Iovino

MD

Azienda Ospedaliero, Universitaria Pisana

研究点 (1)

Loading locations...

相似试验

Zinc as Enhancer in Immune Recovery After Stem Cell... | 临床试验